Enterprise Value

545.3M

Cash

209.1M

Avg Qtr Burn

-42.22M

Short % of Float

11.04%

Insider Ownership

1.25%

Institutional Own.

95.89%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XMT-2056 (HER2 ADC) Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1

Data readout

XMT-1660 (B7-H4 ADC) Details
Cancer, Ovarian cancer, Endometrial cancer, Breast cancer

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

XMT-1592 (NaPi2b antigen) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Failed

Discontinued